Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
1 Университет им. Давида Бен-Гуриона в Негеве. 8410501, Израиль, Беер-Шева. 2 ГБОУ ВПО «Ставропольский государственный медицинский университет» Минздрава России. 355017, Россия, Ставрополь, ул. Мира, д. 310.
Список исп. литературыСкрыть список 1. Беккер Р. А., Быков Ю. В. Мемантин: возможности и перспективы применения в психиатрии (Обзор современных данных). Психиатрия и психофармакотерапия им. П. Б. Ганнушкина. 2016; 4 (18): 42–51. 2. Беккер Р. А., Быков Ю. В. Мемантин: обзор применения в неврологии. Психиатрия и психофармакотерапия. 2017; 19 (1): 34–43. 3. Беккер Р. А., Быков Ю. В. Роль мемантина в терапии постинсультных состояний: механизм действия и практические результаты. Психиатрия и психофармакотерапия им. П. Б. Ганнушкина. 2017; 03: 44–53. 4. AAVV, NICE. Alzheimer's disease—donepezil, galantamine, rivastigmine (review) and memantine, Technology Appraisal Guidance 111, 2007, http://guidance.nice.org.uk/TA111. 5. Allen LV. Memantine Hydrochloride 2 mg/mL Oral Solution, Thickened. US Pharm. 2017;42(11):47–48. 6. Allepaerts S, Delcourt S, Petermans J. [Swallowing disorders in elderly patients: a multidisciplinary approach].[Article in French]. Rev Med Liege. 2014;69(5–6):349–56. 7. Allgaier M, Allgaier C. An update on drug treatment options of Alzheimer's disease. Front Biosci (Landmark Ed). 2014;19:1345–1354. 8. Aracava Y, Pereira EF, Maelicke A, Albuquerque EX. Memantine blocks alpha7* nicotinic acetylcholine receptors more potently than n-methyl-D-aspartate receptors in rat hippocampal neurons. J Pharmacol Exp Ther. 2005;312(3):1195–1205. 9. Bello O, Blair K, Chapleau C, Larimore JL. Is memantine a potential therapeutic for Rett syndrome? Front Neurosci. 2013;7:245. 10. Bisaga A, Comer SD, Ward AS et al. The NMDA antagonist memantine attenuates the expression of opioid physical dependence in humans. Psychopharmacology. 2001;157(1):1–10. 11. Boinpally R, Chen L, Zukin SR et al. A novel once-daily fixed-dose combination of memantine extended release and donepezil for the treatment of moderate to severe Alzheimer’s disease: two phase I studies in healthy volunteers. Clin Drug Invest. 2015;35(7):427–435. doi: 10.1007/s40261-015-0296-4. 12. Bramwell BL. Compliance to treatment in elderly dysphagic patients: potential benefits of alternate dosage forms. IJPC. 2009;13:498–505. 13. Brennan BP, Roberts JL, Fogarty KV et al. Memantine in the treatment of binge eating disorder: an open-label, prospective trial. Int J Eat Disorder. 2008;41(6):520–526. 14. Bresink I, Benke TA, Collett VJ, et al. Effects of memantine on recombinant rat NMDA receptors expressed in HEK 293 cells. Br J Pharmacol. 1996;119(2):195–204. 15. Brown PD, Shook S, Laack NN et al. Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiation therapy (WBRT): first report of RTOG 0614, a placebo-controlled, double-blind, randomized trial. Int J Radiat Oncol Biol Phys. 2012;13(3):S1–S2. 16. Buisson B, Bertrand D. Open-channel blockers at the human alpha4beta2 neuronal nicotinic acetylcholine receptor. Mol Pharmacol. 1998;53(3): 555–563. 17. Cacabelos R, Takeda M, Winblad B. The glutamatergic system and neurodegeneration in dementia: preventive strategies in Alzheimer's disease. Int J Geriatr Psychiatry. 1999 ;14(1):3–47. 18. Chen HS, Lipton SA. Mechanism of memantine block of NMDA-activated channels in rat retinal ganglion cells. J Physiol. 1997;499(Pt 1):27–49. 19. Chen HS, Pellegrini JW, Aggarwal SK, et al. Open-channel block of N-methyl-D-aspartate (NMDA) responses by memantine: therapeutic advantage against NMDA receptor-mediated neurotoxicity. J Neurosci. 1992;12(11):4427–4436. 20. Del Río-Sancho S, Serna-Jiménez CE, Sebastián-Morelló M et al. Transdermal therapeutic systems for memantine delivery. Comparison of passive and iontophoretic transport. Int J Pharm. 2017;517(1):104–111. doi: 10.1016/j.ijpharm.2016.11.038. 21. Di Iorio G, Baroni G, Lorusso M et al. Efficacy of Memantine in Schizophrenic Patients: A Systematic Review. J Amino Acids. 2017;2017:7021071. 22. Diehl-Schmid J, Forstl H, Perneczky R et al. A 6-month, open-label study of memantine in patients with frontotemporal dementia. Int J Geriatr Psychiatry. 2008;23(7):754–759. 23. Dziewas R, Beck AM, Clave P et al. Recognizing the Importance of Dysphagia: Stumbling Blocks and Stepping Stones in the Twenty-First Century. Dysphagia. 2017;32(1):78–82. 24. Ferguson JM, Shingleton RN. An open-label, flexible-dose study of memantine in major depressive disorder. Clin Neuropharmacol. 2007;30(3):136–144. 25. Findling RL, McNamara NK, Stansbrey RJ et al. A pilot evaluation of the safety, tolerability, pharmacokinetics, and effectiveness of memantine in pediatric patients with attention-deficit/hyperactivity disorder combined type. J Child Adolesc Psychopharmacol. 2007;17(1):19–33. 26. Fischer PA, Jacobi P, Schneider E, Schonberger B. Effects of intravenous administration of memantine in parkinsonian patients. Arzneimittelforschung. 1977;27(7):1487–1489. 27. Folch J, Busquets O, Ettcheto M et al. Memantine for the Treatment of Dementia: A Review on its Current and Future Applications. J Alzheimers Dis. 2018;62(3):1223–1240. 28. Granderath FA, Kamolz T, Pointner R. Gastroesophageal reflux disease: principles of disease, diagnosis, and treatment. Springer Science and Business Media, 2006. ISBN 978-3709116715. 344 pages. 29. Horner J, Alberts MJ, Dawson DV, Cook GM. Swallowing in Alzheimer’s disease. Alzheimer Dis Assoc Disord. 1994;8:177–179. 30. Jacobs CS, Willment KC, Sarkis RA. Non-invasive Cognitive Enhancement in Epilepsy. Front Neurol. 2019;10:167. 31. Kelly J, D'Cruz G, Wright D. Patients with dysphagia: Experiences of taking medication. J Adv Nurs. 2010;66(1):82–91. 32. Kishita N, Backhouse T, Mioshi E. Nonpharmacological interventions to improve depression, anxiety, and quality of life (QoL) in people with dementia: an overview of systematic reviews. J Geriatr Psychiatry Neurol. 2019;33:28–41. 33. Kumar S. Memantine: pharmacological properties and clinical uses. Neurol India. 2004;52(3):307–309. 34. Kuns B, Varghese D. Memantine. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020. 35. Levin OS, Batukaeva LA, Smolentseva IG, Amosova NA. Efficacy and safety of memantine in dementia with Lewy bodies. Zh Nevrol Psikhiatr Im S S Korsakova. 2008;108(5):39–46. 36. Lima S, Gago M, Garrett C, Pereira MG. Medication adherence in Alzheimer’s disease: the mediator role of mindfulness. Arch Gerontol Geriatr. 2016;67:92–97. doi: 10.1016/j.archger.2016.06.021. 37. Lipton SA. Failures and successes of NMDA receptor antagonists: molecular basis for the use of open-channel blockers like memantine in the treatment of acute and chronic neurologic insults. NeuroRx. 2004;1(1):101–110. 38. Lipton SA. Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond. Nat Rev Drug Discov. 2006;5(2):160–170. 39. Lipton SA. Pathologically-activated therapeutics for neuroprotection: mechanism of NMDA receptor block by memantine and S-nitrosylation. Curr Drug Targets. 2007;8(5):621–632. 40. Maekawa Y, Hasegawa S, Ishizuka T et al. Pharmacokinetics and Bioequivalence of Memantine Tablet and a New Dry Syrup Formulation in Healthy Japanese Males: Two Single-Dose Crossover Studies. Adv Ther. 2019;36(10):2930–2940. doi: 10.1007/s12325-019-01044-y. 41. McShane R, Areosa Sastre A, Minakaran N. Memantine for dementia. The Cochrane database of systematic reviews. 2006;(2):CD003154 10.1002/14651858.CD003154.pub5. 42. Muhonen LH, Lonnqvist J, Juva K, Alho H. Double-blind, randomized comparison of memantine and excitalopram for the treatment of major depressive disorder comorbid with alcohol dependence. J Clin Psychiatry. 2008;69(3):392–399. 43. Muñoz A, Agudelo G, Lopera F. Diagnóstico del estado nutricional de los pacientes con demencia tipo Alzheimer registrados en el Grupo de Neurociencias, Medellín, 2004. Biomédica. 2006;26:113–125. 44. Na R, Yang JH, Yeom Y et al. A systematic review and meta-analysis of nonpharmacological interventions for moderate to severe dementia. Psychiatry Investig. 2019;16:325–335. 45. Namenda (memantine) package insert. Irvine, CA: Allergan USA, Inc; 2016. 46. Namenda XR (memantine hydrochloride). Full Prescribing Information, Forest Pharmaceuticals Inc., St. Louis, MO, 2014. 47. Ney DM, Weiss JM, Kind AJ, Robbins J. Senescent swallowing: impact, strategies, and interventions. Nutr Clin Pract. 2009;24(3):395–413. 48. Niederhofer H. Glutamate antagonists seem to be slightly effective in psychopharmacologic treatment of autism. J Clin Psychopharmacol. 2007;27(3):317–318. 49. Noguchi Y, Saito S. Needs for dosage forms required in dementia patients. Pharm Stage. 2011;10(10):32–36. 50. Ondo WG, Mejia NI, Hunter CB. A pilot study of the clinical efficacy and safety of memantine for Huntington’s disease. Parkinsonism Relat Disord. 2007;13(7):453–454. 51. Orlando RC. Gastroesophageal reflux disease. CRC Press, 2000. ISBN 978-0824703899. 368 pages. 52. Pellegrini JW, Lipton SA. Delayed administration of memantine prevents N-methyl-D-aspartate receptor-mediated neurotoxicity. Ann Neurol. 1993;33(4):403–407. 53. Plosker GL. Memantine extended release (28 mg once daily): a review of its use in Alzheimer’s disease. Drugs. 2015;75(8):887–897. doi: 10.1007/s40265-015-0400-3. 54. Ridha BH, Josephs KA, Rosser MN. Delusions and hallucinations in dementia with Lewy bodies: worsening with memantine. Neurology. 2005;65(3):481–482. 55. Rogawski MA, Wenk GL. The neuropharmacological basis for the use of memantine in the treatment of Alzheimer's disease. CNS Drug Rev. 2003;9(3):275–308. 56. Rustembegovic A, Kundurovic Z, Sapcanin A, Sofic E. A placebo-controlled study of memantine (Ebixa) in dementia of Wernicke-Korsakoff syndrome. Med Arh. 2003;57(3):149–150. 57. Scheltens P, Blennow K, Breteler MMB, et al. Alzheimer’s disease. Lancet. 2016;388:505–517. 58. Schindler JS, Kelly JH. Swallowing disorders in the elderly. Laryngoscope. 2002;112(4):589–602. 59. Schley M, Topfner S, Wiech K et al. Continuous brachial plexus blockade in combination with the NMDA-receptor antagonist memantine prevents phantom limb pain in acute traumatic upper limb amputees. Eur J Pain. 2007;11(3):299–308. 60. Schneider E, Fischer PA, Clemens R et al. Effects of oral memantine administration on Parkison symptoms. Results of a placebo-controlled multicenter study. Dtsch Med Wochenschr. 1984;109(25):987–990. 61. Schneider LS, Dagerman KS, Higgins JP, McShane R. Lack of evidence for the efficacy of memantine in mild Alzheimer disease. Arch Neurol. 2011;68(8):991–998. 62. Serra G, Demontis F1, Serra F et al. Memantine: New perspective in bipolar disorder treatment. World J Psychiatry. 2014 Dec;4(4):80–90. 63. Shanmugam S, Karunaikadal K, Varadarajan S, Krishnan M. Memantine Ameliorates Migraine Headache. Ann Indian Acad Neurol. 2019;22(3):286–290. 64. Sinis N, Birbaumer N, Gustin S, et al. Memantine treatment of complex regional pain syndrome: a preliminary report of six cases. Clin J Pain. 2007;23(3):237–243. 65. Stahl SM. Stahl’s Essential Psychopharmacology: Prescriber’s Guide. Cambridge university press, 2017. ISBN 978-1316618134. 890 pages. 66. Stahl SM. Stahl's Essential Psychopharmacology. Neuroscientific Basis and Practical Application. Cambridge University Press, 4th Ed. 2013. ISBN 978-1107025981. 628 pages. 67. Sunada H, Bi Y. Preparation, evaluation and optimization of rapidly disintegrating tablets. Powder Technol. 2002;122:188–198. doi: 10.1016/S0032-5910(01)00415-6. 68. Tricco AC, Ashoor HM, Soobiah C et al. Comparative effectiveness and safety of cognitive enhancers for treating Alzheimer’s disease: systematic review and network metaanalysis. J Am Geriatr Soc. 2018;66:170–178. 69. Tu S, Okamoto S, Lipton SA, Xu H. Oligomeric Aβ-induced synaptic dysfunction in Alzheimer's disease. Mol Neurodegener. 2014;9:48. 70. Vorwerk CK, Lipton SA, Zurakowski D et al. Chronic low-dose glutamate is toxic to retinal ganglion cells. Toxicity blocked by memantine. Invest Ophthalmol Vis Sci. 1996;37(8):1618–1624. 71. Wong KH, Riaz MK, Xie Y et al. Review of Current Strategies for Delivering Alzheimer's Disease Drugs across the Blood-Brain Barrier. Int J Mol Sci. 2019;20(2).